Skip to main content

Table 2 Comparison between survival-related genes and cancer driver genes

From: Survival-related genes are diversified across cancers but generally enriched in cancer hallmark pathways

Cancer Type # of SRGsa DriverDBV3
Mutationb CNV Methylation
Log-Rank Test
 KIRC 7770 46.9% (340/725) ** 0% (0/3) 50% (6/12)
 LGG 6691 32.5% (570/1752) 82.2% (37/45) ***  
 ACC 5243 19.7% (74/375) 32.3% (40/124)  
 UVM 3765 25% (9/36) 62% (75/121) ***  
 LIHC 2359 9.5% (106/1113) 9.6% (8/83) 6.6% (12/181)
 PRAD 1538 5.1% (58/1141) 23.5% (4/17) 4.4% (3/68)
 MESO 586 2.5% (1/40) 0% (0/1)  
 PAAD 443 1.6% (16/971) 0% (0/2) 16% (4/25)**
 KIRP 238 1.9% (12/631) 1.1% (1/87) 2.2% (5/224)
 BLCA 39 0.2% (6/2404) 0% (0/104) 0% (0/443)
 CESC 35 0.2% (4/1815) 0% (0/52)  
 LAML 29 0% (0/413) 0% (0/3)  
 HNSC 18 0% (0/1914) 1% (1/103) 0% (0/89)
 STAD 10 0.1% (4/3695) 0% (0/86)  
 LUAD 8 0% (1/2903) 0% (0/37) 0% (0/18)
 SKCM 1 0% (0/4559) 0% (0/18)  
Cox Regression
 KIRC 7091 38.3% (278/725) 0% (0/3) 50% (6/12)
 ACC 6467 25.9% (97/375) 43.5% (54/124)  
 UVM 5600 33.3% (12/36) 84.3% (102/121) ***  
 LGG 5418 27.2% (476/1752) 42.2% (19/45) ***  
 PAAD 4287 21.2% (206/971) 0% (0/2) 36% (9/25)*
 LIHC 2384 10% (111/1113) 8.4% (7/83) 9.9% (18/181)
 PRAD 2068 8.1% (92/1141) 35.3% (6/17) * 5.9% (4/68)
 MESO 728 2.5% (1/40) 0% (0/1)  
 KIRP 592 2.4% (15/631) 2.3% (2/87) 1.8% (4/224)
 BLCA 442 2.7% (64/2404) 1% (1/104) 1.6% (7/443)
 KICH 407 3.7% (2/54)   
 CESC 230 1.4% (25/1815) 0% (0/52)  
 HNSC 204 0.9% (17/1914) 1.9% (2/103) 0% (0/89)
 LAML 158 0.7% (3/413) 0% (0/3)  
 LUAD 71 0.4% (12/2903) 5.4% (2/37) ** 0% (0/18)
 PCPG 64 2% (1/49) 0% (0/5)  
 BRCA 24 0.1% (2/2162) 0% (0/220) 0% (0/36)
 UCEC 5 0% (0/6669) 0% (0/76)  
 STAD 3 0% (1/3695) 0% (0/86)  
 SARC 2 0% (0/543) 0% (0/104)  
 THCA 2 0% (0/192) 0% (0/3) 0% (0/201)
  1. Note: Fisher’s exact test of SRGs and cancer driver genes; *p < 0.05, **p < 0.01, ***p < 0.001, one-tailed. The first number in the parentheses indicates the count of overlapping genes between SRGs and cancer driver genes, and the second number indicates total driver genes that are also applicable genes in specified cancer
  2. - Not available; no driver genes were described in those cancer types
  3. aSRGs for both models are defined as FDR < 0.05
  4. bMutation-based driver genes were merged based on 14 tools summarized by DriverDBV3